Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGC

Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with pr

PolyPid Ltd. (PYPD) Analyst/Investor Day Transcript

PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or th

PolyPid NASDAQ: PYPD outlined plans to expand its commercial and development strategy through 2030 a

Analysts initiated coverage: Hold ALHC; Overweight/$6 SPRO; Buy/$3 LABT; Buy/$6 CLOV.

Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Jo

Analysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperf

Oppenheimer analyst Les Sulewski initiates coverage on PolyPid (NASDAQ:PYPD) with a Outperform ra

Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with simila

Management to outline ‘PolyPid 2030', the Company's long-term vision and pipeline strategy Event to

PolyPid (NASDAQ: PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candi

PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candida

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Las

PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or th

PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or t

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensu

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or th

The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act ("PDU

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previous

Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut

Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals ​to commer

PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 mi

PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceu

If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical sit

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.41) per share which missed the analyst consen

PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma com

Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.37) per share which beat the analyst consensu

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma comp

Craig-Hallum analyst Chase Knickerbocker maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers th

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.78) per share which missed the analyst consen